Search results for "multiple sclerosis"

showing 10 items of 630 documents

Incidence of multiple sclerosis in Bagheria City, Sicily, Italy.

2001

We investigated the incidence of multiple sclerosis (MS) in a Sicilian community located at sea level. The study was a retrospective search for MS patients. Incidence was studied in the period from 1 January 1985 to 31 December 1994. We searched for definite MS patients, according to Poser's criteria, among the population resident in Bagheria (Palermo province). There were 25 subjects affected by MS, of which 20 were incident MS patients. The average annual incidence was 4.4 per 100 000 persons (n = 453 385 person-years). The incidence increased over time (1985-1989 = 3.5, 1990-1994 = 5.3). A parallel decrease of the interval between onset and diagnosis of MS was observed (1985-1989, 3.7 ye…

AdultMalemedicine.medical_specialtyPediatricsMultiple SclerosisAdolescentEpidemiologyPopulationDermatologyAnnual incidenceCohort StudiesEpidemiologymedicinePrevalenceHumansMultiple sclerosieducationSicilyRetrospective Studieseducation.field_of_studyNeuroscience (all)business.industryMultiple sclerosisIncidence (epidemiology)IncidenceGeneral MedicineMiddle Agedmedicine.diseaselanguage.human_languagePsychiatry and Mental healthCross-Sectional StudieslanguageSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessSicilianNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct

Three years of experience : the Italian registry and safety data update

2011

At the end of 2006, a pharmacovigilance program on natalizumab was settled by the Italian Pharmaceutical Agency, and on January 2007, multiple sclerosis patients poorly responding to the immunomodulating therapies or with an aggressive clinical form of disease from onset initiated to be registered and to receive the medication. On February 2010, almost 3,000 cases have been treated with natalizumab. The drop-out rate is 10%. Almost 800 cases received cycles of natalizumab for more than 18 months. One case of PML was reported and other adverse events are similar to those described in phase III studies. The majority of cases remained stable, while in 25% of cases, an improvement of disability…

AdultMalemedicine.medical_specialtyPediatricsMultiple SclerosisDermatologyDiseaseAntibodies Monoclonal HumanizedNatalizumabPharmacovigilanceProduct Surveillance PostmarketingmedicineHumansRegistriesAdverse effectbusiness.industryNatalizumabMultiple sclerosisGeneral Medicinemedicine.diseasePsychiatry and Mental healthItalyPHARMACOVIGILANCEREGISTRYsurveillance program; pharmacovigilance; multiple sclerosis; natalizumabPhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)NeurosurgerybusinessMultiple sclerosis NatalizumabSurveillance program Pharmacovigilancemedicine.drug
researchProduct

The pharmacovigilance program on natalizumab in Italy: 2 years of experience.

2009

At the end of 2006 a country-based surveillance program on natalizumab therapy in multiple sclerosis was settled in Italy by a collaborative effort of the Italian Drug Agency (AIFA) and a group of experts and neurologists appointed by the National Society of Neurology (SIN). After 2 years, 1,818 patients are registered in the database. The majority of cases (88.6%) failed the therapy with beta interferon or glatiramer acetate and had relapses or accumulated disability during immunomodulating treatment, while 11.4% of patients enrolled in the surveillance study were not previously treated with immunomodulating therapies and had a rapidly evolving clinical course. Almost 10% of the patients t…

AdultMalemedicine.medical_specialtyPediatricsNeurologyMultiple SclerosisPatient DropoutsDatabases FactualAlternative medicineDermatologyPharmacologyAntibodies Monoclonal HumanizedNatalizumabPharmacovigilanceProduct Surveillance PostmarketingMedicineHumansGlatiramer acetateMultiple sclerosis NatalizumabSurveillance programPharmacovigilancebusiness.industryMultiple sclerosisNatalizumabAntibodies MonoclonalDrug agencyGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingPsychiatry and Mental healthItalyPHARMACOVIGILANCEREGISTRYSettore MED/26 - NeurologiaFemaleNeurology (clinical)Neurosurgerybusinessmedicine.drugFollow-Up StudiesNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct

Trace elements in scalp hair samples from patients with relapsing-remitting multiple sclerosis

2015

Background Epidemiological studies have suggested a possible role of trace elements (TE) in the etiology of several neurological diseases including Multiple Sclerosis (MS). Hair analysis provides an easy tool to quantify TE in human subjects, including patients with neurodegenerative diseases. Objective To compare TE levels in scalp hair from patients with MS and healthy controls from the same geographic area (Sicily). Methods ICP-MS was used to determine the concentrations of 21 elements (Ag, Al, As, Ba, Cd, Co, Cr, Cu, Fe, Li, Mn, Mo, Ni, Pb, Rb, Sb, Se, Sr, U, V and Zn) in scalp hair of 48 patients with relapsing–remitting Multiple Sclerosis compared with 51 healthy controls. Results MS …

AdultMalemedicine.medical_specialtyPercentilePathologylcsh:MedicineGastroenterologyIndirect evidenceMultiple sclerosisMultiple Sclerosis Relapsing-RemittingInternal medicinemedicineHuman scalp hairHumanslcsh:ScienceAgedTrace elementsMultidisciplinaryExpanded Disability Status ScaleScalpChemistryMultiple sclerosisSignificant differenceHair analysislcsh:RMiddle Agedmedicine.diseaseRubidiumTrace ElementsSettore GEO/08 - Geochimica E Vulcanologiamedicine.anatomical_structureRelapsing remittingScalpUraniumFemalelcsh:QAluminumHairResearch Article
researchProduct

Biomedical Variables and Adaptation to Disease and Health-Related Quality of Life in Polish Patients with MS

2018

The aim of this research was to assess the level of adaptation to multiple sclerosis (Sclerosis multiplex

AdultMalemedicine.medical_specialtyacceptance of illnessMultiple SclerosisNeurologyHealth Toxicology and Mutagenesislcsh:MedicineDiseaseSeverity of Illness IndexArticleDisability Evaluation03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Adaptation PsychologicalmedicineHumansDisabled Persons030212 general & internal medicineAge of OnsetMobility LimitationAdaptation (computer science)Mood Disordersbusiness.industryneurologyMedical recordMultiple sclerosislcsh:RPublic Health Environmental and Occupational HealthMiddle Agedmedicine.diseaseAdaptation Physiologicalhumanitieschronic illness; disability; acceptance of illness; neurology; mood disorders; fatigue; quality of lifedisabilityquality of lifeMood disordersPopulation studyfatigueFemalePolandbusinesschronic illness030217 neurology & neurosurgeryClinical psychologyInternational Journal of Environmental Research and Public Health
researchProduct

Possible Role of Butyrylcholinesterase in Fat Loss and Decreases in Inflammatory Levels in Patients with Multiple Sclerosis after Treatment with Epig…

2021

(1) Background. Multiple sclerosis (MS) is characterised by the loss of muscle throughout the course of the disease, which in many cases is accompanied by obesity and related to inflammation. Nonetheless, consuming epigallocatechin gallate (EGCG) and ketone bodies (especially β-hydroxybutyrate (βHB)) produced after metabolising coconut oil, have exhibited anti-inflammatory effects and a decrease in body fat. In addition, butyrylcholinesterase (BuChE), seems to be related to the pathogenesis of the disease associated with inflammation, and serum concentrations have been related to lipid metabolism. Objective. The aim of the study was to determine the role of BuChE in the changes caused after…

AdultMalemedicine.medical_specialtyfood.ingredientPilot ProjectsEpigallocatechin gallatemultiple sclerosisAntioxidantsCatechinArticlechemistry.chemical_compoundfoodβ-hydroxybutyrateInternal medicineWeight LossmedicineHumansTX341-641ObesityButyrylcholinesteraseNutrition and DieteticsbiologyNutrition. Foods and food supplybusiness.industryCoconut oilParaoxonaseAlbuminMiddle AgedLipid Metabolismmedicine.diseaseObesityPON1EndocrinologyAdipose TissuechemistryinflammationDietary SupplementsbutyrylcholinesteraseCoconut Oilbiology.proteinKetone bodiesFemalebusinessEGCGFood ScienceNutrients
researchProduct

Effect of organizational features on patient satisfaction with care in Italian multiple sclerosis centres

2017

Background and purpose Receiving clear, complete and up-to-date information and having a satisfying relationship with the health professional (HP) are of primary importance for MS patients. Healthcare organization plays a key role in promoting an effective relationship and communication between patients and HPs. The present study aims to explore which care organization and service characteristics provided by Italian MS centres best predict patients’ satisfaction with healthcare. Methods Eighty-one centres and 707 patients (502 women, mean age 40.5 years, SD 10.2; mean education 12.2 years, SD 3.6; time since diagnosis 5.9 years, SD 1.5) were included in the analysis. The care organization a…

AdultMalemedicine.medical_specialtymedia_common.quotation_subjectPsychological interventionNicehealth professional-patient relationshipmultiple sclerosiscare organization; health professional-patient relationship; multiple sclerosis; patients’ satisfaction; psychological support03 medical and health sciences0302 clinical medicinePatient satisfactionCare organizationExcellenceSurveys and QuestionnairesHealth caremedicineHumans030212 general & internal medicinepatients’ satisfactioncomputer.programming_languagemedia_commonPhysician-Patient Relationsbusiness.industryMultiple sclerosisMiddle Agedmedicine.diseaseConfidence intervalItalyNeurologyPatient SatisfactionFamily medicineFemalecare organizationNeurology (clinical)businessDelivery of Health CareCare Organization Health professional–Patient Relationship Multiple Sclerosis Patients’ Satisfaction Psychological Supportcomputer030217 neurology & neurosurgerypsychological supportEuropean Journal of Neurology
researchProduct

Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis

2020

Abstract An ever-expanding number of disease-modifying drugs for multiple sclerosis have become available in recent years, after demonstrating efficacy in clinical trials. In the real-world setting, however, disease-modifying drugs are prescribed in patient populations that differ from those included in pivotal studies, where extreme age patients are usually excluded or under-represented. In this multicentre, observational, retrospective Italian cohort study, we evaluated treatment exposure in three cohorts of patients with relapsing-remitting multiple sclerosis defined by age at onset: paediatric-onset (≤18 years), adult-onset (18–49 years) and late-onset multiple sclerosis (≥50 years). We…

AdultMalemedicine.medical_specialtyneuroinflammationCohort Studies03 medical and health sciences0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicinemedicineHumansDisabled Persons030212 general & internal medicineProspective StudiesRisk factorclinical trials; clinically isolated syndrome; demyelination; multiple sclerosis epidemiology; neuroinflammationRetrospective Studiesclinical trialsClinically isolated syndromeExpanded Disability Status ScaleProportional hazards modelbusiness.industryHazard ratioMiddle AgedItalyAntirheumatic Agentsclinically isolated syndromeCohortDisease Progressionmultiple sclerosis epidemiologySettore MED/26 - NeurologiaFemaleNeurology (clinical)demyelinationAge of onsetbusiness030217 neurology & neurosurgeryCohort studyFollow-Up Studies
researchProduct

Grey matter damage and overall cognitive impairment in primary progressive multiple sclerosis

2011

Objectives: To identify associations between cognitive impairment and imaging measures in a cross-sectional study of patients with primary progressive multiple sclerosis (PPMS). Methods: Neuropsychological tests were administered to 27 patients with PPMS and 31 controls. Patients underwent brain conventional magnetic resonance imaging (MRI) sequences, volumetric scans and magnetization transfer (MT) imaging; MT ratio (MTR) parameters, grey matter (GM) and normal-appearing white matter (NAWM) volumes, and WM T2 lesion load (T2LL) were obtained. In patients, multiple linear regression models identified the imaging measure associated with the abnormal cognitive tests independently from the ot…

AdultMalemedicine.medical_specialtyprimary progressive multiple sclerosisAudiologyGrey matterNeuropsychological TestsWhite matterExecutive FunctionCognitionMemoryPredictive Value of TestsLondonmedicineHumansAttentionEffects of sleep deprivation on cognitive performanceAgedChi-Square Distributionmedicine.diagnostic_testSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaVerbal BehaviorMultiple sclerosisNeuropsychologyBrainCognitionMagnetic resonance imagingMiddle AgedMultiple Sclerosis Chronic Progressivemedicine.diseaseMagnetic Resonance ImagingCognitive testmedicine.anatomical_structureCross-Sectional StudiesNeurologyCase-Control StudiesLinear ModelsFemaleNeurology (clinical)PsychologyCognition DisordersNeuroscience
researchProduct

The impact of isolated lesions on white-matter fiber tracts in multiple sclerosis patients

2015

Infratentorial lesions have been assigned an equivalent weighting to supratentorial plaques in the new McDonald criteria for diagnosing multiple sclerosis. Moreover, their presence has been shown to have prognostic value for disability. However, their spatial distribution and impact on network damage is not well understood. As a preliminary step in this study, we mapped the overall infratentorial lesion pattern in relapsing–remitting multiple sclerosis patients (N = 317) using MRI, finding the pons (lesion density, 14.25/cm3) and peduncles (13.38/cm3) to be predilection sites for infratentorial lesions. Based on these results, 118 fiber bundles from 15 healthy controls and a subgroup of 23 …

AdultPathologymedicine.medical_specialtyWallerian degenerationCognitive Neurosciencelcsh:Computer applications to medicine. Medical informaticsArticlelcsh:RC346-429LesionWhite matterMultiple sclerosisMultiple Sclerosis Relapsing-RemittingNerve FibersLSAF left superior arcuate fasciculusFractional anisotropymedicineHumansRadiology Nuclear Medicine and imagingFA fractional anisotropyNAWM normal-appearing white matterLD lesion densitylcsh:Neurology. Diseases of the nervous systemEAE experimental autoimmune encephalomyelitisMD mean diffusivitybusiness.industryMultiple sclerosisWhite matterMcDonald criteriaMiddle Agedmedicine.diseaseRD radial diffusivitymedicine.anatomical_structureDiffusion tensor imagingNeurologylcsh:R858-859.7Neurology (clinical)Brainstemmedicine.symptomFunction and Dysfunction of the Nervous SystembusinessBrainstemAD axial diffusivityDiffusion MRIBrain StemICP inferior cerebellar peduncleFractional anisotropyNeuroImage: Clinical
researchProduct